Medications commonly prescribed for T2D, including glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and pioglitazone, have well-described anti-inflammatory effects and may have lowered circulating IL-6 in treated individuals [31]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.